0000000000073578

AUTHOR

Antonio Massimo Ippolito

showing 3 related works from this author

HCV genotype 1a and 1b: Similarities and differences in clinical features, therapeutic outcome and predictors of response

2014

medicine.medical_specialtyHepatologyGenotype 1bbusiness.industryInternal medicineGastroenterologymedicinebusinessOutcome (game theory)Digestive and Liver Disease
researchProduct

Variation in genes encoding for interferon λ-3 and λ-4 in the prediction of HCV-1 treatment-induced viral clearance

2013

Background & Aims In patients with chronic HCV-1 infection, recent evidences indicate that determination of a dinucleotide polymorphism (ss469415590, ΔG/TT) of a new gene, designated IFN λ-4, might be more accurate than the 12979860CC type of the IL28B locus in predicting sustained virological response (SVR) following peg-interferon and ribavirin. In addition, combined genotyping of different SNPs of the IL28B locus was shown to help dissect patients most prone to SVR among those with rs12979860CT. We examined whether single or combined genotyping of two IL28B SNPs, rs12979860 and rs8099917, and ss469415590 variation might improve the prediction of SVR. Results In the study cohort of 539 pa…

MaleOncologySettore MED/09 - Medicina InternaIL28Bpeg-interferonBioinformaticsPolyethylene GlycolLinkage DisequilibriumPolyethylene GlycolsCohort StudiesIL28B/interferon lambda-3 genechemistry.chemical_compoundGene Frequencypeg-interferon/ribavirinvirus diseasesRecombinant ProteinMiddle AgedViral LoadHepatitis CRecombinant ProteinsTreatment OutcomeHCVCohortFemaleHumanAdultmedicine.medical_specialtyinterferon lambda-3 geneLocus (genetics)Single-nucleotide polymorphismBiologychronic hepatitiInternal medicineRibavirinmedicineHumansSNPAlleleGenotypingGeneinterferon lambda-4 geneAgedPolymorphism GeneticHepatologyInterleukinsRibavirinInterferon-alphaInterleukindigestive system diseaseschemistryInterferonsCohort StudieLiver International
researchProduct

HCV genotype 1 subtypes (1a and 1b): similarities and differences in clinical features and therapeutic outcome.

2015

Aim: To evaluate similarities and differences in HCV-1 subtypes 1a and 1b in the presenting clinical features and the response to peg-interferon and ribavirin (Peg/RIBA).Patients and methods: A total of 1,233 naïve patients with HCV genotype-1 infection, 159 (13 %) with subtype 1a and 1,074 (87 %) with subtype 1b were treated with Peg-IFN/RIBA at 12 Italian centers. Covariates included in the logistic model were age, gender, BMI, serum alanine aminotransferase, serum gamma-glutamiltranspeptidase (γGT), platelets counts, liver fibrosis, the occurrence of type 2 diabetes, baseline viremia, and IL28B genotype.Results: At multivariate analysis, baseline characteristics differentiating patients …

Liver CirrhosisMaleMultivariate analysisclinical featuresChronic HCV liver diseaseType 2 diabetesSex FactorHepacivirusGastroenterologyPolyethylene GlycolPolyethylene Glycolstherapeutic outcomechemistry.chemical_compoundGenotypeAge FactorSettore MED/12 - GastroenterologiaSustained virologic responseAge Factorsvirus diseasesHCV genotype 1 subtypes (1a and 1b)Hepatitis CRecombinant ProteinMiddle AgedRecombinant ProteinsTreatment OutcomeInterferonRNA ViralFemaleHCV subtypeHumanAdultmedicine.medical_specialtyGenotypeLiver CirrhosiAlpha interferonmacromolecular substancesInterferon alpha-2Antiviral AgentsSex FactorsDiabetes mellitusInternal medicineRibavirinmedicineHumansPeg-interferon and ribavirinAntiviral AgentHepaciviruHepatologybusiness.industryRibavirinInterleukinstechnology industry and agricultureInterferon-alphaHepatologyInterleukinHepatitis C Chronicmedicine.diseaseVirologydigestive system diseaseschemistryDiabetes Mellitus Type 2HCV genotypeHCV genotype 1 subtypes (1a and 1b); clinical features; therapeutic outcomeInterferonshepatitis Cbusiness
researchProduct